Dana-Farber Cancer Institute

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Dana-Farber Cancer Institute

https://www.dana-farber.org/

LYNKED IN Patient Conference 2024
Multiple Myeloma Patient Symposium
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business

Playback speed

10 seconds

Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targeted Therapy in NSCLC

By Dana-Farber Cancer Institute FEATURING Biagio Ricciuti

228 views

May 22, 2024

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Lung

Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targe…

Dana-Farber Cancer Institute

B. Ricciuti

228 views

Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, …

Dana-Farber Cancer Institute

B. Ricciuti

238 views

ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro Comb…

ecancer

P. Janne

98 views

WCLC 2023 Insights: "Association of TTF-1 Expression With Outcomes t…

Insights from 2023 WCLC

A. Di Federico

88 views

WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhibitor…

Insights from 2023 WCLC

B. Ricciuti

98 views

WCLC 2023 Insights: "3-Year Outcomes & Correlative Analyses in Patie…

Insights from 2023 WCLC

B. Ricciuti

101 views

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Dana-Farber Cancer Institute

J. Sands

611 views